Rankings
▼
Calendar
ALNY Q4 2025 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
ALNY
Alnylam Pharmaceuticals, Inc.
$43B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$1.1B
+84.9% YoY
Gross Profit
$829M
75.6% margin
Operating Income
$132M
12.0% margin
Net Income
$186M
17.0% margin
EPS (Diluted)
$1.37
QoQ Revenue Growth
-12.2%
Cash Flow
Operating Cash Flow
$164M
Free Cash Flow
$140M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$5.0B
Total Liabilities
$4.2B
Stockholders' Equity
$789M
Cash & Equivalents
$1.7B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$1.1B
$593M
+84.9%
Gross Profit
$829M
$490M
+69.1%
Operating Income
$132M
-$105M
+225.3%
Net Income
$186M
-$84M
+322.6%
Revenue Segments
GIVLAARI
$161M
69%
ONPATTRO
$71M
31%
Geographic Segments
UNITED STATES
$1.2B
78%
Europe
$233M
15%
Non-US Or Europe
$107M
7%
← FY 2025
All Quarters